Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals

Melikhov, O.G.; Kruglova, Tatiana S.; Lytkina, K.; Melkonyan, G.G.; Прохорович, Е. А.; Putsman, G.A.; Родоман, Г. В.; Vertkin, A L; Zagrebneva, Alena I.; Stebbing, Justin

doi:10.1136/annrheumdis-2021-220049

Cited by 11 publications

(12 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Zhu et al [ 14 ] reported on tofacitinib treatment of refractory cutaneous leukocytoclastic vasculitis. In infectious diseases, Tatiana [ 15 ] reported that tofacitinib was effective in 320 patients with COVID-19; this study evaluated a prospective observational series. Tong found that tofacitinib reduced death or respiratory failure at 28 days in patients hospitalized with COVID-19 pneumonia [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib

Luo

Chen

et al. 2022

Eur J Med Res

View full text Add to dashboard Cite

Background Dermatomyositis is a rare idiopathic inflammatory disease with diverse presentations that can have varying degrees of cutaneous and systemic involvement. This phenotypic heterogeneity makes DM a therapeutic challenge. Some therapeutic drugs, such as hormones and immunosuppressants, have poor therapeutic effects. In recent years, tofacitinib has been reported to be effective in the treatment of dermatomyositis. Case presentation We report a case of anti-MDA5 antibody-positive dermatomyositis that was relieved after treatment with tofacitinib, during which gallbladder gangrene and suppurative cholecystitis occurred. After cholecystectomy, we continued to use tofacitinib and achieved a good therapeutic effect. Conclusions Tofacitinib is effective in the treatment of anti-MDA5 antibody-positive dermatomyositis, but the risk of infection is increased. It can still be used after infection control. Close follow-up should be performed during the use of tofacitinib.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib

Luo

Chen

et al. 2022

Eur J Med Res

View full text Add to dashboard Cite

show abstract

“…Baricitinib is a Janus associated kinase (JAK) inhibitor, which was primarily used for treatment of rheumatoid arthritis [49][50][51]. It has a good safety and efficacy profile, despite some concerns [52][53][54][55]. Baricitinib is able to modulate the cytokine storm through the JAK-STAT pathway [56][57][58][59][60][61][62].…”

Section: Baricitinib Olumiant®mentioning

confidence: 99%

Oral anti-COVID-19 drugs that were recently evaluated by FDA or EMA: a review

Lorenz¹,

Pawliczak²

2022

pja

View full text Add to dashboard Cite

COVID-19 is an infectious disease that is caused by coronavirus SARS-CoV-2. As the time passed it became clear that, aside from the vaccines, other efficient methods of fighting the disease are urgently needed. Among the whole list of medicines used to treat COVID-19, those which are administered orally have a great advantage. The aim of this paper is to present the current knowledge about the recently investigated oral medications for COVID-19. The authors present molnupiravir (Lagevrio), baricitinib (Olumiant) and ritonavir + PF-07321332 (Paxlovid). All of these drugs have been registered recently or are waiting for authorization by EMA or FDA. During the study, the authors learned that huge progress was made, nevertheless, more studies are needed, especially in the field of side effects and drug-drug interactions of the considered substances.

show abstract

“…In this themed issue of the Annals of the Rheumatic Diseases, focused on COVID-19 and SARS-CoV-2 vaccination in rheumatology, a number of papers have been assembled, which advance our understanding in this area and should allow for optimising the approach to this pandemic in the near future. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] To date, our understanding of COVID-19 risk in rheumatology comes primarily from observational registry-based cohorts. A clear signal has emerged in that patients receiving B-cell depletion therapy or high-dose glucocorticoids at baseline are at higher risk of more severe COVID-19 outcomes if infected.…”

Section: Editorialmentioning

confidence: 99%

SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future

2021

View full text Add to dashboard Cite

Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals

Abstract: To cite Melikhov O, Kruglova T, Lytkina K, et al. Ann Rheum Dis Epub ahead of print: [please include Day Month Year].

Cited by 11 publications

References 7 publications

Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib

Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib

Oral anti-COVID-19 drugs that were recently evaluated by FDA or EMA: a review

SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future

Contact Info

Product

Resources

About